120
Participants
Start Date
November 11, 2014
Primary Completion Date
October 18, 2019
Study Completion Date
June 1, 2023
BI 836845
Enzalutamide
Enzalutamide
National Taiwan University Hospital, Taipei
NewYork-Presbyterian/Weill Cornell Medical Center, New York
Taipei Veterans General Hospital, Taipei
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Ramón y Cajal, Madrid
Taichung Veterans General Hospital, Taichung
Instituto Valenciano de Oncología, Valencia
Karmanos Cancer Institute, Detroit
Oregon Health and Sciences University, Portland
National Cancer Centre Singapore, Singapore
OncoCare Cancer Centre, Singapore
Tan Tock Seng Hospital, Singapore
Prince of Wales Hospital, Hong Kong
Queen Mary Hospital, Hong Kong
Erasmus MC - Daniel den Hoed, Rotterdam
Tweesteden Ziekenhuis, locatie Tilburg, Tilburg
Samsung Medical Center, Seoul
Asan Medical Center, Seoul
Hospital Vall d'Hebron, Barcelona
Hospital Clínic de Barcelona, Barcelona
Hospital Santa Creu i Sant Pau, Barcelona
Hospital Duran i Reynals, L'Hospitalet de Llobregat
The Clatterbridge Cancer Centre, Bebington, Wirral
Velindre Cancer Centre, Cardiff
The Christie Hospital, Manchester
Churchill Hospital, Oxford
The Royal Marsden Hospital, Sutton, Sutton
Lead Sponsor
Boehringer Ingelheim
INDUSTRY